Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
CADILA HEALTHCARE | SANOFI INDIA | CADILA HEALTHCARE/ SANOFI INDIA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 29.9 | 42.5 | 70.4% | View Chart |
P/BV | x | 4.8 | 8.7 | 55.7% | View Chart |
Dividend Yield | % | 0.7 | 1.0 | 71.2% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CADILA HEALTHCARE Mar-20 |
SANOFI INDIA Dec-18 |
CADILA HEALTHCARE/ SANOFI INDIA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 352 | 6,840 | 5.2% | |
Low | Rs | 207 | 4,630 | 4.5% | |
Sales per share (Unadj.) | Rs | 139.2 | 1,203.1 | 11.6% | |
Earnings per share (Unadj.) | Rs | 11.8 | 165.3 | 7.1% | |
Cash flow per share (Unadj.) | Rs | 18.6 | 209.9 | 8.8% | |
Dividends per share (Unadj.) | Rs | 3.50 | 84.00 | 4.2% | |
Dividend yield (eoy) | % | 1.3 | 1.5 | 85.5% | |
Book value per share (Unadj.) | Rs | 101.4 | 963.6 | 10.5% | |
Shares outstanding (eoy) | m | 1,023.74 | 23.03 | 4,445.2% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.0 | 4.8 | 42.1% | |
Avg P/E ratio | x | 23.7 | 34.7 | 68.4% | |
P/CF ratio (eoy) | x | 15.0 | 27.3 | 55.1% | |
Price / Book Value ratio | x | 2.8 | 6.0 | 46.3% | |
Dividend payout | % | 29.8 | 50.8 | 58.5% | |
Avg Mkt Cap | Rs m | 286,033 | 132,078 | 216.6% | |
No. of employees | `000 | 13.4 | 3.3 | 406.1% | |
Total wages/salary | Rs m | 24,145 | 4,068 | 593.5% | |
Avg. sales/employee | Rs Th | 10,632.7 | 8,393.8 | 126.7% | |
Avg. wages/employee | Rs Th | 1,801.2 | 1,232.4 | 146.2% | |
Avg. net profit/employee | Rs Th | 898.5 | 1,153.0 | 77.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 142,531 | 27,708 | 514.4% | |
Other income | Rs m | 1,139 | 897 | 127.0% | |
Total revenues | Rs m | 143,670 | 28,605 | 502.3% | |
Gross profit | Rs m | 24,198 | 6,235 | 388.1% | |
Depreciation | Rs m | 6,965 | 1,027 | 678.2% | |
Interest | Rs m | 3,418 | 7 | 48,828.6% | |
Profit before tax | Rs m | 14,954 | 6,098 | 245.2% | |
Minority Interest | Rs m | 288 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 3,198 | 2,292 | 139.5% | |
Profit after tax | Rs m | 12,044 | 3,806 | 316.4% | |
Gross profit margin | % | 17.0 | 22.5 | 75.4% | |
Effective tax rate | % | 21.4 | 37.6 | 56.9% | |
Net profit margin | % | 8.5 | 13.7 | 61.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,154 | 15,922 | 547.4% | |
Current liabilities | Rs m | 82,694 | 6,235 | 1,326.3% | |
Net working cap to sales | % | 3.1 | 35.0 | 9.0% | |
Current ratio | x | 1.1 | 2.6 | 41.3% | |
Inventory Days | Days | 71 | 64 | 112.2% | |
Debtors Days | Days | 94 | 21 | 449.6% | |
Net fixed assets | Rs m | 133,236 | 7,539 | 1,767.3% | |
Share capital | Rs m | 1,024 | 230 | 445.2% | |
"Free" reserves | Rs m | 102,733 | 21,962 | 467.8% | |
Net worth | Rs m | 103,757 | 22,192 | 467.5% | |
Long term debt | Rs m | 32,146 | 0 | - | |
Total assets | Rs m | 236,866 | 29,839 | 793.8% | |
Interest coverage | x | 5.4 | 872.1 | 0.6% | |
Debt to equity ratio | x | 0.3 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.9 | 64.8% | |
Return on assets | % | 6.5 | 12.8 | 51.1% | |
Return on equity | % | 11.6 | 17.2 | 67.7% | |
Return on capital | % | 13.7 | 27.5 | 49.9% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 52,752 | 7,587 | 695.3% | |
Fx outflow | Rs m | 14,504 | 7,145 | 203.0% | |
Net fx | Rs m | 38,248 | 442 | 8,653.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25,054 | 3,739 | 670.1% | |
From Investments | Rs m | -10,123 | -731 | 1,384.8% | |
From Financial Activity | Rs m | -10,942 | -1,972 | 554.9% | |
Net Cashflow | Rs m | 3,989 | 1,036 | 385.0% |
Indian Promoters | % | 74.8 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 60.4 | - | |
Indian inst/Mut Fund | % | 8.3 | 14.4 | 57.6% | |
FIIs | % | 5.9 | 14.6 | 40.4% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 11.0 | 10.5 | 104.8% | |
Shareholders | 44,069 | 15,184 | 290.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CADILA HEALTHCARE With: STRIDES PHARMA SCIENCE AJANTA PHARMA SUVEN LIFE SCIENCES ALEMBIC PHARMA WOCKHARDT
Compare CADILA HEALTHCARE With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.
For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Ajit Dayal on the investing strategy for 2021 and beyond.
More